Latest publications

House dust mite sublingual allergen immunotherapy tablet is safe and well-tolerated in Dutch clinical practice. Tempels-Pavlica Ž, Aarts MCJ, Welsing PMJ, Van der Meer AN, Van der Zwan LP, Uss E et al. Front Allergy 2024; 5:1355324

Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy. Achten R, Thijs J, Van der Wal M, Van Luijk C, Bakker D, Knol E et al. Clin Exp Allergy 2024 Feb 08

Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry. Kamphuis E, Boesjes CM, Loman L, Kamsteeg M, Haeck I, Van Lynden-van Nes AMT et al. Acta Derm Venereol 2024 Feb 07; 104:adv19454

Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis. Clabbers J, Boesjes C, Spekhorst L, Van Gisbergen MW, Maas E, Marshall J et al. J Allergy Clin Immunol 2024 Apr; 153(4):1155-1161.e4

Mental Health of School-Aged Children Treated with Propranolol or Atenolol for Infantile Hemangioma and Their Parents. Hermans MM, Schappin R, De Laat PCJ, Mendels EJ, Breur JMPJ, Langeveld HR et al. Dermatology 2024; 240(2):216-225

Differential dynamics of TARC during JAK-inhibitor therapy compared to biological therapies targeting type 2 inflammation. Boesjes CM, Bakker DS, Knol EF, De Graaf M, Van Wijk F, De Bruin-Weller MS et al. Clin Exp Allergy 2023 Dec 30

Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis. Silverberg JI, De Bruin-Weller M, Calimlim BM, Hu X, Ofori SA, Platt AM et al. Dermatitis 2023 Dec 18

Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S et al. Lancet 2024 Jan 13; 403(10422):147-159

Effectiveness of antibacterial therapeutic clothing vs. nonantibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: a randomized controlled observer-blind pragmatic trial (ABC trial). Ragamin A, Schappin R, De Graaf M, Tupker RA, Fieten KB, Van Mierlo MMF et al. Br J Dermatol 2024 Feb 16; 190(3):342-354

Prevalence of chronic urticaria and healthcare usage of patients with the condition in primary care: a population-based study in the Netherlands. Soegiharto R, Westmeijer M, Boekema-Bakker N, Groenewegen IAM, Knulst AC, Van den Reek JMPA et al. Br J Dermatol 2024 Jan 23; 190(2):287-289

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D et al. N Engl J Med 2023 Oct 26; 389(17):1579-1589

Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis. Boesjes CM, Van der Gang LF, Bakker DS, Ten Cate TA, Spekhorst LS, De Graaf M et al. JAMA Dermatol 2023 Nov 01; 159(11):1240-1247

Systemic anti-inflammatory treatment of atopic dermatitis during conception, pregnancy and breastfeeding: Interdisciplinary expert consensus in Northern Europe. Deleuran M, Dézfoulian B, Elberling J, Knutar I, Lapeere H, Lossius AH et al. J Eur Acad Dermatol Venereol 2024 Jan; 38(1):31-41

A concept for integrated care pathways for atopic dermatitis-A GA LEN ADCARE initiative. Zuberbier T, Abdul Latiff A, Aggelidis X, Augustin M, Balan RG, Bangert C et al. Clin Transl Allergy 2023 Sep; 13(9):e12299

IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval. Dekkers C, Van der Wal MM, Van den Noort L, Bakker DS, De Bruin-Weller M, Van Wijk F et al. Clin Exp Allergy 2023 Nov; 53(11):1222-1225